FDA approves new imaging agent for Alzheimer’s disease detection
The FDA approved Tauklarify, a tau PET imaging agent, for detecting tau pathology in adults evaluated for Alzheimer’s disease.
Read More
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
Alzheimer’s Disease
FDA approves Leqembi Iqlik subcutaneous injection as starting dose for early Alzheimer’s disease
The FDA approved Leqembi Iqlik subcutaneous injections as a once-weekly starting dose for early Alzheimer’s disease treatment at home.
Read More
FDA Approves Blood Test for Early Alzheimer’s Risk Detection Using Neutrophil Inflammation Marker
The FDA approved the Lumipulse G pTau217/ß-Amyloid 1-42 blood test for early Alzheimer’s detection in adults 55+ with cognitive decline.
Read More
Hydrogen Sulfide Gas from CSE Protein Emerges as Potential Alzheimer’s Treatment Target
Johns Hopkins researchers identify CSE enzyme and hydrogen sulfide as potential targets to prevent Tau protein-related Alzheimer’s progression.
Read More